HBW 3210
Alternative Names: HBW-3-10; HBW-3210Latest Information Update: 09 Jul 2025
At a glance
- Originator Chengdu Hyperway Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II B-cell lymphoma
- Phase I Autoimmune disorders; Chronic lymphocytic leukaemia
Most Recent Events
- 09 Jul 2025 Phase-I trials in Autoimmune disorders in China (PO) (Chengdu Hyperway Pharmaceuticals pipeline, July 2025)
- 25 Jul 2022 Phase I trials in Chronic lymphocytic leukaemia in China (PO) as of July 2022 (Chengdu Hyperway Pharmaceuticals pipeline, July 2022)
- 25 Jul 2022 Preclinical trials in Autoimmune disorders in China (PO) (Chengdu Hyperway Pharmaceuticals pipeline, July 2022)